Unique ID issued by UMIN | UMIN000043639 |
---|---|
Receipt number | R000049837 |
Scientific Title | Study on therapeutic effect and safety for combination of immune checkpoint inhibitor and molecular-targeted therapies for unresectable hepatocellular carcinoma |
Date of disclosure of the study information | 2021/03/17 |
Last modified on | 2024/09/18 09:09:15 |
Study on effect and safety for combination of immune checkpoint inhibitor and molecular-targeted therapies for liver cancer
Study on treatment effect with anti-cancer agents for liver cancer
Study on therapeutic effect and safety for combination of immune checkpoint inhibitor and molecular-targeted therapies for unresectable hepatocellular carcinoma
Study on Biomarkers in treatment with anti-cancer agents for hepatocellular carcinoma
Japan |
unresectable hepatocellular carcinoma
Hepato-biliary-pancreatic medicine |
Malignancy
NO
The aim of this study is to examine the clinical course and patients' characteristics before and after treatment of patients treated with combination therapy of immune checkpoint inhibitors and molecular targeted therapies in a clinical setting. The analysis in this study includes the change of serum cytokine/chemokine, the population of immune-cells, and gut-microbiota.
Safety,Efficacy
Investigating the biomarkers on the therapeutic effects in short- and long-term periods.
Investigating the biomarkers on side effects.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Clinically diagnosed as HCC
No indication for local treatment such as liver resection, liver transplantation, or radiofrequency ablation
Having a treatable liver function
Performance status of 0-2 on ECOG
Age is 20 years or older.
Informed consent has been obtained
Patients who wish to be excluded from the study.
Patients who are pregnant, lactating, may become pregnant, or intend to become pregnant, or who wish to have a baby.
Patients with the following serious complications:
1.Cardiovascular abnormalities such as heart failure, angina pectoris, or arrhythmia that are difficult to control even after treatment.
2. Myocardial infarction within 6 months of onset
3. Renal failure
4. Active infectious disease except for viral hepatitis
5. Active gastrointestinal bleeding
6. Other active cancer requiring treatment
7. Hepatic encephalopathy or severe mental disorder
8. Severe drug allergy
9. Serious autoimmune disease.
Other conditions that the physician deems inappropriate for the safe conduct of this study.
100
1st name | Masatoshi |
Middle name | |
Last name | Ishigami |
Nagoya University Graduate School of Medicine
Gastroenterology and Hepatology
466-8560
65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan.
0527442169
masaishi@med.nagoya-u.ac.jp
1st name | Takanori |
Middle name | |
Last name | Ito |
Nagoya University Hospital
Gastroenterology and Hepatology
466-8560
65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan.
0527412169
tahkun56@med.nagoya-u.ac.jp
Nagoya University Hospital
Nagoya University Hospital
Self funding
Ogaki Municipal Hospital
Kariya Toyota general hospital
Tosei General Hospital
Toyohashi Municipal Hospital
Fujita Health University
National Center for Global Health and Medicine
Nagoya University Graduate School of Medicine
65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8560, Japan.
0527442423
tahkun56@med.nagoya-u.ac.jp
NO
2021 | Year | 03 | Month | 17 | Day |
Unpublished
91
No longer recruiting
2020 | Year | 11 | Month | 09 | Day |
2020 | Year | 11 | Month | 09 | Day |
2020 | Year | 12 | Month | 01 | Day |
2025 | Year | 08 | Month | 31 | Day |
2023 | Year | 12 | Month | 31 | Day |
None
2021 | Year | 03 | Month | 17 | Day |
2024 | Year | 09 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049837